Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
  • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
  • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

• the present invention provides a 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine for the preparation of a pharmaceutical composition for the treatment of malignant neoplasia.
• the invention provides a method for the treatment of malignant neoplasia, the method comprising the steps of administering 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine to a subject in need thereof and a pharmaceutical composition comprising 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine.
• Advanced malignant neoplasias are characterized by a locally infiltrative disease and the formation of one or multiple microscopic or macroscopic local or distant metastases. It is known in the art for such neoplasias that a concomitant phenomenon is the development of resistance to conventional chemotherapy regimens. Examples are recurrent malignant glioma, advanced breast cancer, advanced ovarian cancer, advanced prostate cancer, advanced malignant melanoma, or multiple myeloma. These neoplasias are typically not amenable to curative local treatment, such as e.g. surgery or local radiation therapy, but instead require the systemic administration of therapeutic agents, typically chemotherapeutic regimens. Even the use of chemotherapeutics, containing a combination of different agents in order to impede the development of chemoresistance to single agents and to optimize the tolerability of the usually highly toxic regimens to patients fails in a significant number of cases.
• Chemotherapy regimens used to treat advanced stage cancers include second line alkylating agents such as melphalan, platinum-containing compounds, topoisomerase inhibitors, or antimetabolites, are associated with extremely toxic effects on bone marrow and other organs, limiting therapeutic or palliative administration [3-5].
• second line alkylating agents such as melphalan, platinum-containing compounds, topoisomerase inhibitors, or antimetabolites
• IPA 4-lodo-L- phenylalanine
• IPA-123 iodine-123 labeled analogue 4-[ 123 l]iodo-L-phenylalanine (IPA-123) demonstrated the effectiveness and safety of single photon emission tomography (SPET) with IPA-123 for brain tumour imaging [8, 9].
• SPET single photon emission tomography
• IPA-123 crosses according to [8, 9] the blood-brain barrier after intravenous administration and accumulates specifically in malignant gliomas with prolonged retention in tumor.
• a series of amino acid derivatives have been tested for their antineoplastic activities in antitumor screens [10-15]. They include the halobenzoyl-DL-phenylalanines, N- chloroacetyl derivatives of para-substituted phenylalanines, N-benzoyl- fluorophenylalanine, p-chloro-DL-phenylalanine, ⁇ -methyl-phenylalanine, N-ethylcarb- aminomethyl-L-isoleicine and N-propionyl-L-valine, to name only some.
• the administration of all compounds from said group is also known to be associated with extremely toxic side effects on bone marrow and other organs, limiting therapeutic or palliative administration.
• the present invention relates to a use of 3-iodo-L-phenylalanine or 4-iodo- L-phenylalanine for the preparation of a pharmaceutical composition for the treatment of malignant neoplasia.
• X is an iodine linked to L-phenylalanine at the 3- (meta-) or the 4- (para-) position within the aromatic ring.
• Ri is H, alkyl group, amino acid, peptide, protein or other residues known to facilitate or improve tumor targeting.
• R2 is OH, amino acid, or other residues known to facilitate or improve tumor targeting.
• the 3-iodo-L-phenylalanine may also be designated meta-iodo-L-phenylalanine (IMA) and the 4-iodo-L-phenylalanine as para-iodo-L-phenylalanine (IPA). It is preferred that Ri is H and R 2 is OH.
• the iodine conjugated to the L-phenylalanine is the stable, non-radioactive [ 127 l]-iodine isotope.
• malignant neoplasia describes in the context of the present invention a cancer, carcinoma, sarcoma, or other tumor, characterised by progressive, uncontrolled, invasive and or metastatic growth. A malignant neoplasia leads invariably to death if not treated.
• An indication for the administration of a pharmaceutical composition comprising 3- iodo-L-phenylalanine or 4-iodo-L-phenylalanine to a subject with malignant neoplasia is also the diagnosis of minimal residual disease, preferably an early solid tumor, advanced solid tumor or metastatic solid tumor, which is characterized by the local and non-local recurrence of the tumor caused by the survival of single cells.
• pharmaceutical composition relates to a composition for administration to a subject, preferably a human patient.
• the pharmaceutical composition is preferably administered orally, parenterally, transdermal ⁇ , intraluminally, intra-arterially, intrathecal ⁇ or intravenously.
• a direct injection of the pharmaceutical composition into malignant tissue is administered to a patient via infusion or injection, or as a tablet or capsule.
• Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, subcutaneous, intraperitoneal, intramuscular, topical or intradermal administration.
• the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.
• suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions, etc. Compositions comprising such carriers can be formulated by well known conventional methods.
• compositions can be administered to the subject at a suitable dose.
• the dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Preferred dosages for the administration of the 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine are described herein below.
• the compositions may be administered locally or systemically. Administration will generally be parenteral, e.g., intravenous, or oral. In an preferred embodiment, the pharmaceutical composition is administered subcutaneously and in an even more preferred embodiment intravenously.
• the pharmaceutical composition is administered orally.
• Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
• non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
• Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
• Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
• Intravenous vehicles include fluid and nutrient replenishes, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.
• the pharmaceutical composition might comprise proteinaceous carriers, like, e.g., serum albumin or immunoglobulin, preferably of human origin.
• the pharmaceutical composition might comprise, in addition to 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine further biologically active agents, depending on the intended use of the pharmaceutical composition in a treatment comprising the administration of additional agents for a concomitant therapy.
• further biologically active agents are described herein below in the context of uses and methods comprising a concomitant therapy.
• a cytotoxic effect of the identified phenylalanine derivatives on all tested malignant cell lines is already detectable for concentrations in a range of 0.1 to 0.3 ⁇ mol/ml, which may be roughly translated in a human dose in the range of 7 to 21 mmol / 70 kg body weight, corresponding to a dose of 2 to 6 g / kg body weight, assuming even distribution throughout the body.
• 2-iodo-L-phenylalanine an example for an ortho-isomer of the 4-(para)iodo-L-phenylalanine (IPA) and the halogenated D-phenylalanine analogues revealed only low uptake and a moderate cytotoxity in neoplastic cells compared with IPA and IMA. This shows the superior effect of 3-iodo-L-phenylalanine and 4-iodo-L-phenylalanine on malignant cells and tissues compared to other compounds.
• IPA 4-(para)iodo-L-phenylalanine
• IMA halogenated D-phenylalanine
• the specific accumulation of the 3-iodo-L-phenylalanine and 4-iodo-L-phenylalanine leads to a surprisingly marked retention by the malignant cells or tissue.
• the 3- iodo-L-phenylalanine or 4-iodo-L-phenylalanine has a cytostatic effect on such malignant cells or tissue.
• said halogenated-L-phenylalanines such as 4- iodo-L-phenylalanine (IPA) show marked antitumor activities and enhance radiosensitivity in primary tumor cells, including human glioblastoma, prostatic, ovarian and breast cancer, multiple myeloma and malignant melanoma.
• the LD 50 is > 100 mg/kg in rats [9].
• the LD 10 for IPA administered via i.p. injection has been determined in experiments as >27 mg/kg in rats.
• the LD 5O described for L-phenylalanine administered via i.p. injection is according to the manufacturer 5280 mg/kg in rats.
• the toxicity of 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine is in an acceptable ratio of effectivity vs.
• said 3-iodo-L-phenylalanine and 4-iodo-L-phenylalanine represent an attractive new class of compounds for therapeutic pharmaceuticals for the treatment of tumors by which an effective cytotoxic dose can be concentrated selectively on the devastating tumor cells, while sparing the normal tissues.
• the halogenated- L-phenylalanine with iodine in 3- (meta-) or 4-(para-) position are cytostatically active compounds which show favorable tolerability profiles.
• a therapy using the halogenated-L-phenylalanines 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine can thereby overcome cellular detoxicfication strategies. Due to the anti-tumor activity the compound is an alternative for maintenance or induction therapy in advanced cancers and for the improvement of the tolerability and efficacy of existing chemotherapy regimens.
• the pharmaceutical composition is to be administered to a subject, wherein 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine is generally administered in a dose of 0.001 to 100 mg/kg body weight of the subject. More preferably, the 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine is in a dose of 0.1 to 25 mg/kg body weight of the subject and more preferably, the 3-iodo-L- phenylalanine or 4-iodo-L-phenylalanine is in a dose of 1.0 to 25 mg/kg body weight of the subject.
• the halogenated-L-phenylalanine is 4-iodo-L-phenylalanine.
• the malignant neoplasia is selected from a group consisting of malignant glioma, multiple myeloma, malignant melanoma, prostatic and breast cancer. More preferably, the glioma is selected from the group consisting of glioblastoma multiforme, anaplastic astrozytoma, astrooligodendroglioma, oligoastrozytoma and ependymoma.
• the 3-iodo-L-phenylalanine or 4- iodo-L-phenylalanine has on the malignant cells or tissue of the neoplasia a radiosensitizing effect, a cytostatic effect and/or an effect to revert an acquired or constitutive state of cellular resistance to chemotherapy or radiotherapy.
• cytostatic effect describes in the context of the present invention the capacity of a compound to slow down or to arrest the cell proliferation of malignant cells.
• radiosensitizing effect describes in the context of the present invention the capacity of a compound to enhance the therapeutic response to concomitantly administered radiation therapy, wherein the radiation therapy includes external or internal radiation therapy, corresponding to the induction of an increased response to a given radiation dose administered in the presence of the radiosensitizing compound, compared to the response induced by the same radiation dose in the absence of the radiosensitizing compound, or alternatively the selective induction of the sensitivity of neoplastic cells for a radiotherapy, not present in the absence of the compound.
• an effect to revert an acquired or constitutive state of cellular resistence to chemotherapy or radiotherapy describes in the context of the present invention the capacity of a compound to convert or to reconvert the cellular sensitivity for a chemotherapy or a radiotherapy.
• the pharmaceutical composition further comprises a chemotherapeutic agent, an immunotherapeutic agent, a gene therapeutic agent, a vaccine, an antisense nucleotide therapeutic agent, an siRNA therapeutic agent and/or an endoradiotherapeutic agent.
• chemotherapeutic agent an immunotherapeutic agent, a gene therapeutic agent, a vaccine, an antisense nucleotide therapeutic agent, an siRNA therapeutic agent and/or an endoradiotherapeutic agent is understood as a concomitant therapy.
• Methods and means for such concomitant therapies are well known in the art.
• the 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine and the additional therapeutic agent may be formulated as a single pharmaceutical composition for simultaneous administration of the effective compounds or in separate pharmaceutical compositions for sequential administration. Accordingly, an administration of a composition comprising 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine prior to the administration of a composition comprising one or more therapeutics selected from the group of a chemotherapeutic, an immunotherapeutic, a gene therapeutic, a vaccine, an antisense nucleotide therapeutic, an siRNA therapeutic and an endoradiotherapeutic agent is envisaged as well as simultaneous or subsequent administration.
• chemotherapeutic agent comprises bioactive agents known to be effective in retarding or arresting the malignant growth or to be effective in the regression or elimination of malignant tissues or cells.
• agents might be e.g. drugs acting as cytostatics.
• a chemotherapy comprises in line with the medical standards in any systemic or local treatment the administration of cytostatic or cytotoxic agents.
• Chemotherapeutic agents used in oncology include among others, nitroso urea compunds (ACNU [nimustin], BCNU [carmustin], CCNU [lomustin]), temozolomid, procarbacin, metothrexate, cytarabin, gemcitabine, fluorouracil, cyclophosphamide, mitoxantron, anthracyclins, estramustin, or taxanes.
• the chemotherapeutic agents are intended to be administered in appropriate dosing regimens according to medical practice.
• nitroso urea compounds, temozolomide, procarbacin, and methotrexate are preferred chemotherpeutic agents.
• an immunotherapeutic agent comprise but are not limited to compounds such as antibodies, antibody fragments and/or derivatives thereof which specifically detect malignant tissue or cells and/or cellular therapeutics, including those consisting of adoptively transferred autologous, heterologous, xenogenous or endogenous cells, which have the ability to eliminate malignant cells or tissues.
• antibody fragment or derivative thereof relates to single chain antibodies, or fragments thereof, synthetic antibodies, antibody fragments, such as Fab, a F(ab2)', Fv or scFv fragments, single domain antibodies etc., or a chemically modified derivative of any of these.
• Antibodies to be employed in accordance with the invention or their corresponding immunoglobulin chain(s) can be further modified outside the motifs using conventional techniques known in the art, for example, by using amino acid deletion(s), insertion(s), substitution(s), addition(s), and/or recombination(s) and/or any other modification(s) (e.g. posttranslational and chemical modifications, such as glycosylation and phosphorylation) known in the art either alone or in combination.
• modification(s) e.g. posttranslational and chemical modifications, such as glycosylation and phosphorylation
• a tumor-specific marker is a tumor-associated cell surface antigen which is either found exclusively on tumor cells or is overexpressed on tumor cells as compared to non- malignant cells.
• Tumor-associated cell surface antigens can be expressed not only on tumor cells but also on cells/tissue which are/is not essential for survival or which can be replenished by stem cells not expressing tumor-associated cell surface antigen. Furthermore, a tumor-associated cell surface antigen can be expressed on malignant cells and non-malignant cells but is better accessible by a therapeutic agent of interest on malignant cells. Examples of over-expressed tumor-associated cell surface antigens are Her2/neu, EGF-Receptor, Her-3 and Her-4. An example of a tumor- associated cell surface antigen which is tumor specific is EGFRV-III. An example of a tumor-associated cell surface antigen which is presented on a cell which is nonessential for survival is PSMA.
• tumor-associated cell surface antigens which are presented on cells which are replenished are CD19, CD20 and CD33.
• immunotherapeutics may comprise agents such as T-cell co-stimulatory molecules or cytokines, agents activating B-cells, NK-cells or other cells of the immune system as well as drugs inhibiting immune reactions (e.g. corticosteroids).
• gene therapeutic agent defines in the context of the invention means for a therapy comprising the administration of one or more nucleic acid constructs functionally encoding e.g. one or more antigens which are characteristic for malignant cells. Such antigens comprise tumor specific markers. The sequence encoding such antigen is operably linked to a nucleic acid sequence which is a regulatory sequence.
• a gene therapy comprises the functional expression of a heterologous gene in a patient according to standard medical protocols using appropriate vector systems known in the art; see e.g. Haberkorn et al., Curr Med Chem. 2005;12(7):779-94.
• regulatory sequence refers to DNA sequences which are necessary to effect the expression of coding sequences to which they are ligated. Control sequences in the context of the described gene therapy generally include promoters, terminators and, in some instances, enhancers, transactivators or transcription factors.
• control sequence is intended to include, at a minimum, all components the presence of which are necessary for expression, and may also include additional advantageous components.
• operably linked refers to an arrangement/configuration wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
• a vaccine aims in the context of the present invention at activating the innate or adaptive immune system of the patient to act against the tumor tissue or the malignant cells.
• Such therapy comprises e.g. administering one or more antigen preparations containing tumor substances, or cells selected to react against tumor tissue or the malignant cells.
• An antisense therapeutic agent is e.g. a nucleotide sequence being complementary to tumor-specific gene sequences, aiming at functionally neutralising tumor gene expression, and consequently inducing tumor cell death.
• siRNA therapeutic agent is e.g. a small interfering RNA capable of sequence- specifically silencing the expression and activity of various tumor-specific target genes by triggering cleavage of specific unique sequences in the mRNA transcript of the target gene and disrupting translation of the target mRNA, consequently inducing tumor cell death.
• a concomitant therapy which requires the administration of one or more additional bioactive agents which is/are effective in the treatment of the malignant neoplasia may be accompanied by the administration of one or more additional compounds which minimize potential side effects of said bioactive agent(s) such as drugs acting on the gastro-intestinal system, drugs preventing hyperuricemia, and/or drugs acting on the circulatory system, e.g. on the blood pressure, known in the art.
• additional bioactive agents may be formulated in the form of the same or a separate pharmaceutical composition.
• endoradiotherapeutic agent defines in the context of the present invention an agent which comprises at least one type of radioactive isotope. Such agent is to be 1? administered to a subject in the need thereof and is effective in the therapy of the above described malignant neoplasia due to an endogenic irradiation, i.e. an irradiation with the radioactive compound within the body of the subject to be treated by the endoradiotherapy.
• the described pharmaceutical composition comprises a combination of 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine, wherein the iodine is the stable, non-radioactive [ 127 l]-iodine isotope and an endoradiotherapeutic agent which is a halogenated-L-phenylalanine, wherein the halogen isotope is selected from the group of alpha-, beta- or Auger-electron emitting isotopes bromine-76, bromine-77, bromine-82, iodine-123, iodine-124, iodine-125, iodine-131 and astatine-211. It is preferred, that the halogen isotope is also conjugated to the L-phenylalanine in 3- (meta-) or 4-(para-) position.
• alpha-, beta- or Auger-electron emitting isotope defines in the context of the present invention radioactive isotopes, characterized by the emission of different particles (rays) formed during radioactive decay or by nuclear transition processes.
• An alpha emitting isotope is defined as a radioactive nuclide emitting alpha particles, corresponding to a helium nucleus consisting of two protons and two neutrons.
• a beta emitting isotope is defined as a nuclide emitting fast nuclear electrons (negatrons) formed during radioactive decay.
• An Auger-electron emitting isotope is defined as a nuclide emitting low energy nuclear electrons, formed by nuclear electron capture or internal transition processes. The maximum path lengths of these particles are in a range from 10 nm to 12 mm.
• the physical half life of the recited radionuclides is 16.2 h for bromine-76, 57.04 h for bromine-77, 35.3 h for bromine-82, 13.27 h for iodine-123, 4.17 d for iodine-124, 59.41 d for iodine-125, 8.02 d for iodine-131 or 7.21 h astatine-211.
• the physical half life of the L-phenylalanine conjugate labelled with these radionuclides corresponds to the half life of the respective radionuclide.
• the preferred mixture of 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine with an endoradiotherapeutic agent is a mixture, wherein the endoradiotherapeutic agent is a halogenated-L-phenylalanine.
• the majority of stable iodine isotopes and some halogen isotopes of the preferred mixture selected from the above identified group of halogen isotopes can be obtained e.g. by a non-isotopic halogen exchange (carrier-added/c.a.).
• 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine 15 comprising only the stable, non-radioactive [ 127 l]-iodine isotope may be mixed with a preparation of halogenated-L-phenylalanine comprising only or in a majority nonstable, radioactive isotopes.
• the latter preparation may be obtained e.g. by a no- carrier-added preparation (n.c.a.) which is essentially free from stable isotopes of the element in question.
• n.c.a. no- carrier-added preparation
• mixtures of stable, non-radioactive preparations with non-stable, radioactive preparations are equally preferred.
• the alpha-, beta- or Auger-electron emitting isotope is administered in doses of 10 "5 to 10 "18 g / kg body. More preferably, the alpha-, beta- or Auger-electron emitting isotope is administered in doses of 10 "7 to 10 ⁇ 15 g /kg body weight and more preferably in doses of 10 "8 to 10 "10 g / kg body weight. It is particularly preferred that such a dose is formulated or contained in 1 to 10, preferably 2 to 5 ml of sterile solution, such as phosphate buffered saline solutions, water for injection, etc.
• sterile solution such as phosphate buffered saline solutions, water for injection, etc.
• the irradiation dose of the alpha-, beta- or Auger- electron emitting isotope is in the range of 0.1 to 1000 MBq/kg body weight. More preferably, the irradiation dose of the alpha-, beta- or Auger-electron emitting isotope is in the range of 10 to 400 MBq/kg body weight and more preferably the irradiation dose of the alpha-, beta- or Auger-electron emitting isotope is in the range of 20 to 120MBq/kg body weight.
• the administered dose is determined using an appropriate dose meter, calibrated to quantitatively measure alpha, beta or gamma radiation.
• the irradiation dose of the alpha-, beta- or Auger-electron emitting isotope is to be administered as a single dose once or as fractionated doses in 2 to 60 fraction doses or as continuous doses given daily until the disease progresses again, or until death of the patient.
• the administration of the described pharmaceutical composition results in an interception or a deceleration of the cancer development due to the cytostatic effect of 3-iodo-L- phenylalanine or 4-iodo-L-phenylalanine. Nevertheless, the disease may further progress after the interception or deceleration and the patient may die.
• the conjugate is to be administered generally fractionized in 2 to 10 fraction doses. It is also preferred that the 3-iodo-L-phenylalanine or 4-iodo-L- phenylalanine is to be administered as a chronic maintenance therapy. It is preferred that the continuous dose is given daily. Dose fractionation is an established procedure in radiation therapy. By fractionating a total administered dose, improved tolerability for healthy non-target tissue, as well as an increased cytotoxic effect to tumor tissue is achieved. Repeated fractionated irradiation allows to therapeutically impact a higher percentage of cells in radiation sensitive stages of the cell cycle, compared to a one time single high dose irradiation.
• Therapeutic irradiation induces single and double strand breaks of DNA, which is counteracted by nuclear repair mechanisms upregulated following irradiation. It is believed, that cells undergoing DNA repair, are more susceptible to a renewed irradiation than radiation-naive cells.
• the radioactive halogen isotopes are p-[ 131 l]iodo-L- phenylalanine (IPA-131), 4-[ 124 l]iodo-L-phenylalanine (IPA-124) and/or p-[ 211 At]astatine-L-phenylalanine (AtPA-211).
• lodine-131 is widely available, has a favourable half life and can be handled by most institutions licensed to apply open radionuclides, lodine-131 allows for the convenient extracorporal therapy monitoring using a gamma camera owing to a gamma ray component, emitted in a fixed ratio relative to the therapeutic beta particle emission, which is itself not detectable extracorporeal ⁇ .
• lodine-124 has a positron emission component, allowing for PET imaging, in addition to the therapeutic beta-emission.
• quantitative PET imaging internal dosimetry measurements at an ongoing basis can be conducted for therapy planning and therapy monitoring for a period of up to 15 days following a single injection.
• Astatine-211 is also preferred, as it emits high energy (6.8 MeV) alpha particles, with a short path length in tissue (65 ⁇ m), allowing to administer a highly cytotoxic radiation to targeted tissue, while minimising undesirable radiation effects to non-target tissue.
• the pharmaceutical composition is to be administered to a patient and that this patient is subsequently irradiated percutaneously (percutaneous radiotherapy or external field radiation therapy).
• external field radiation therapy is understood in the context of the invention as a concomitant therapy.
• External field radiation therapy is typically administered as an external beam radiation stemming from, among others, radioactive cobalt-60 sources, linear accelerators, proton, neutron, or hadron beam sources.
• the irradiation is started in a period of 0 to 7 days subsequent to the administration of the 3-iodine-L-phenylalanine or 4-iodine-L-phenylalanine.
• the irradiation is started in a period of 0.5 to 24 hours subsequent to the administration of the iodine-L-phenylalanine.
• the concomitant radiotherapy may comprise a cumulative external irradiation of a patient in a dose of 1 to 100 Gy.
• a preferred range of the irradiation dose is 1 to 60 Gy.
• the external irradiation dose is administered in 1 to 60 fractional doses, more preferably in 5 to 30 fractional doses.
• the fractionized doses are administered over a period of 1 to 26 weeks, more preferably over a period of 6 to 12 weeks.
• the term 'fractional dose' is to be understood to mean that the overall activity of the fractional dose adds up or essentially adds up to the cumulative external irradiation otherwise also achievable by administering one single dose.
• the invention provides a method for the treatment of malignant neoplasia, the method comprising the steps of administering 3-iodo-L- phenylalanine or 4-iodo-L-phenylalanine to a subject in the need thereof.
• the effective compound 3-iodo-L-phenylalanine or 4-iodo-L- phenylalanine is formulated in form of a pharmaceutical composition.
• pharmaceutical composition has been defined herein above.
• the route of administration of the effective compound depends inter alia on its formulation. Different routes for differentially formulated compositions have been described herein above. It is particularly preferred for the method of the invention that the 3-iodo-L- phenylalanine or 4-iodo-L-phenylalanine is administered intravenously or orally.
• the 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine is administered to the subject in a doses of 0.001 to 100 mg/kg body weight of the subject. More preferably, the 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine is administered in a dose of 0.1 to 25 mg/kg body weight of the subject and more preferably, the 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine is in a dose of 1.0 to 25 mg/kg body weight of the subject.
• Also preferred for the method for the treatment of malignant neoplasia of the invention is the administration of 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine to a subject in the need thereof, wherein the halogenated-L-phenylalanine is 4-iodo-L- phenylalanine.
• the malignant neoplasia is selected from a group consisting of malignant glioma, multiple myeloma, malignant melanoma, prostatic and breast cancer. More preferably, the glioma is selected from the group consisting of glioblastoma, astrozytoma, oligoastrozytoma and ependymoma.
• the 3-iodo-L-phenylalanine or 4- iodo-L-phenylalanine has on the malignant cells or tissue of the neoplasia a radiosensitizing effect, a cytostatic effect and/or an effect to revert an acquired or constitutive state of cellular resistance to chemotherapy or radiotherapy.
• a preferred administration scheme for the administration of the 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine is either the administration of a single dose once or a sequential administration of 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine as fractionated doses in 2 to 60 fraction doses or a continuous dose given until the disease progresses again or until death of the patient/subject.
• the 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine is administered as a chronic maintenance therapy. It is preferred that the continuous dose is given daily.
• the method further comprises the step of treating the subject by a concomitant therapy.
• Said concomitant therapy may be selected from the group consisting of a surgical therapy, a chemotherapy, an endo- or exoradiotherapy, an immunotherapy, a gene therapy, a vaccine therapy, an antisense nucleotide therapy, an siRNA therapy, an intracavitary therapy, or a device-based treatment.
• a chemotherapy an endoradiotherapy or external field radiation therapy (in the following: exoradiotherapy), an immunotherapy, a gene therapy, a vaccine therapy, an antisense nucleotide therapy and an siRNA therapy are provided herein above.
• exoradiotherapy an endoradiotherapy or external field radiation therapy
• an immunotherapy a gene therapy
• a vaccine therapy an antisense nucleotide therapy
• siRNA therapy an siRNA therapy
• a further concomitant therapy in line with the invention comprises the surgical implantation of a radioactive device such as a radioactive seed. Such a seed may be implanted locally to the tumor site.
• a radioactive device such as a radioactive seed.
• the technique of implanting radioactive devices is known in the art and described herein above in the discussion of the state of the art.
• the dose regimen for the administration of the 3-iodo-L-phenylalanine or 4-iodo-L- phenylalanine is preferably in timely accordance with the optional concomitant therapy (e.g. a concomitant external field radiation therapy or a concomitant endoradiotherapy).
• the optional concomitant therapy e.g. a concomitant external field radiation therapy or a concomitant endoradiotherapy.
• 3-iodo-L-phenylalanine or 4-iodo-L- phenylalanine is administered as a chronic maintenance therapy given in combination with other agents to a tumor patient until the disease progresses again or until the death of the patient.
• a method of the invention wherein the concomitant therapy is an exoradiotherapy comprising the step of irradiating the subject percutaneously subsequently to the administration of the 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine. More preferably, the step of irradiating is effected 0 to 7 days subsequent to the administration of the 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine. Even more preferably, the irradiation is started in a period of 0.5 to 24 hours subsequent to the administration of the 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine.
• the above described concomitant radiotherapy may comprise a cumulative external irradiation of a patient in a dose of 1 to 100 Gy.
• a preferred range of the irradiation dose is 1 to 60 Gy.
• the external irradiation dose is administered in 1 to 60 fractional doses, more preferably in 5 to 30 fractional doses.
• the fractionized doses are administered over a period of 1 to 26 weeks, more preferably over a period of 6 to 12 weeks.
• the term 'fractional dose' is to be understood to mean that the overall activity of the fractional dose adds up or essentially adds up to the cumulative external irradiation otherwise also achievable by administering one single dose.
• the above described concomitant therapy comprises the administration of a chemotherapeutic agent, an immunotherapeutic agent, a gene therapeutic agent, an antisense nucleotide therapeutic agent, an siRNA therapeutic agent, a vaccine and/or an endoradiotherapeutic agent or the implantation of a radioactive device. More preferably, the administration of a chemotherapeutic agent, an immunotherapeutic agent, a gene therapeutic agent, an antisense nucleotide therapeutic agent, an siRNA therapeutic agent, a vaccine and/or an endoradiotherapeutic agent is effected prior to, simultaneously and/or subsequently to the administration of the 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine.
• the subject to be treated by the method of the invention is a human subject.
• the invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising 3-iodo-L-phenylalanine or 4-iodo-L-phenylalanine, wherein the iodine is the stable, non-radioactive [ 127 l]-iodine isotope.
• compositions in the context of the present invention have been described in detail herein above. It is preferred that the pharmaceutical composition of the invention further comprises suitable formulations of carrier, stabilizers and/or excipients. Examples for corresponding carrier, stabilizers and/or excipients are known by the person skilled in the art and have been characterized herein above.
• IPA-123 Cellular uptake kinetics of IPA (IPA-123) in human glioma cell lines in vitro
• IPA-123 Cellular uptake kinetics of IPA (IPA-123) in human malignant melanoma cell lines in vitro
• Figure 3 Cellular uptake kinetics of IPA (IPA-123) in human prostate cancer cell lines in vitro
• 4a top left: Dose dependent cytostatic effect of IPA on human Tx3868 glioblastoma cells
• 4b top right: Effect of different doses of external radiation on human Tx3868 glioblastoma cells alone
• 4c bottom left: Dose dependent radiosensitiser effect of IPA administered concomitantly with 5 Gy external radiation on human Tx3868 glioblastoma cells
• 4d bottom right: Dose dependent radiosensitiser effect of IPA administered concomitantly with 10 Gy external radiation on human Tx3868 glioblastoma cells
• 6a top left: Effect of different doses of external radiation on human M059K glioblastoma cells alone
• 6b top right
• 6c bottom left: Cytostatic and radiosensitiser effect of 0.2 mg/ml IPA administered concomitantly with 0 - 15 Gy external radiation on human M059K glioblastoma cells
• 6d bottom right: Cytostatic and radiosensitiser effect of 0.3 mg/ml IPA administered concomitantly with 0 - 15 Gy external radiation on human M059K glioblastoma cells
• 3-lodo-L-phenylalanine (3-IPA), 4-[ 123 l]iodo-L-phenylalanine and 4-iodo-L- phenylalanine (IPA) used in the examples were purchased commercially or prior synthesized as described previously in the literature. Unless stated otherwise, all other chemicals and solvent were of analytical grade.
• human glioma cell lines Five human glioma cell lines, one rat glioma cell line, two human prostate cancer cell lines, as well as one human breast cancer cell line, and a melanoma cell line were investigated.
• the human glioma cell lines Tx 3868 and T 5135 (from primary human glioblastoma multiforme), and the rat C6 glioma cells were provided by the Institute of Human Genetics, University of the Saarland (Homburg, Germany).
• the human high- grade glioma cells designated as A1207, M059K and U373MG, the human prostate cancer cells PC3 and DU425, the pancreatic carcinoma cell line PanC1 , the human breast cancer cell line MCF-07 (American Type Culture Collection, Rockville, MD), and the pancreatic carcinoma cell line PaCa44 (established by Dr Bulow, Mainz, Germany) as well as the melanoma cell lines SK-MEL25 and A101 D were purchased commercially or provided by the oncological research laboratory of the University Medical Center of Saarland (Homburg, Germany).
• Cells were cultivated in RPMI-1640 medium or in Dulbecco's modified Eagle medium (sodium pyruvate-free, supplemented with L-glucose and pyridoxine), respectively, supplemented with 10 % (v/v) heat-inactivated foetal calf serum (FCS), penicillin (50 U/ml), streptomycin (50 ⁇ g/ml), and insulin (50 ⁇ g/ml; PromoCell, Heidelberg, Germany). All cell lines were maintained in appropriate flasks in a humidified incubator (5% CO 2 ) at 37°C.
• FCS foetal calf serum
• penicillin 50 U/ml
• streptomycin 50 ⁇ g/ml
• insulin 50 ⁇ g/ml
• PromoCell Heidelberg, Germany
• Figures 1 - 3 show examples of uptake kinetics of an IPA in human tumor cells.
• the radiolabeled derivative 4-[ 123 l]iodo-L-phenylalanine was used to facilitate quantification, using a gamma counter.
• IPA exhibit high uptake in human tumor cells with a continuous increase over the investigation time. This result provides evidence of the high affinity of the proposed radiopharmaceuticals for human tumors, including the human malignant gliomas, pancreatic carcinomas, prostate and breast cancer.
• cytostatic effect and radiosensitizing effect of IPA in glioma cells are demonstrated in figures 4 - 6.
• the cytostatic effect of IPA on primary human glioblastoma cells is concentration dependent and more pronounced as compared to external irradiation up to 15 Gy (Fig. 4).
• Combining IPA with external irradiation led to a dramatic reduction of cell survival rate.
• Flow-cytometric analyses of stained cells show dose dependent induction of primary necrosis and apoptosis, which was more significant than that caused by external irradiation, even with 15 Gy, and more pronounced with increasing IPA-concentration. This result attests the high radiosensitizing effect of IPA on glioblastoma cells (Fig. 6).
• the surviving cells contained only sparse cytoplasm, the nuclei were shrunken and contained clumped chromatin. Cytologically, the mode of cell death was apoptosis as the remaining tumour cells contained only sparsely cytoplasm and apoptotic bodies, in other cells the nuclei were shrunken and contained condensed chromatin.
• Five out of six untreated rats with A1207 glioblastoma died 12 to 22 days after implantation while four out of six control rats with T3868 died within 28 days. Histological examination of thin brain sections after biopsy confirmed tumors with typical glioblastoma characteristics. In comparison, six out of nine and seven out of nine rats were still alive at day 28 by treatment with IPA (1 and 5 mg / kg), respectively.
• Figure 8 shows an example of survival of untreated and IPA-treated rats with human A1207 glioblastomas according to the Kaplan-Meier method, attesting the effectiveness of IPA in treating gliomas.
• Otani TT Briley MR. Structure-activity relationships among substituted N-benzoyl derivatives of phenylalanine and its analogues in a microbial antitumor prescreen III: derivatives of p-fluoro-DL-phenylalanine. J Pharm Sci. 74(1):40-43, 1985.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Reproductive Health (AREA)
• Physical Education & Sports Medicine (AREA)
• Urology & Nephrology (AREA)
• Gynecology & Obstetrics (AREA)
• Pregnancy & Childbirth (AREA)
• Oncology (AREA)
• Endocrinology (AREA)
• Hematology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Mechanical Treatment Of Semiconductor (AREA)
• Soft Magnetic Materials (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Publications (1)

Family

ID=37744207

Family Applications (1)

Country Status (15)

Cited By (1)

Families Citing this family (1)

Family Cites Families (3)

• 2006
  • 2006-11-27 AU AU2006316781A patent/AU2006316781B2/en active Active
  • 2006-11-27 KR KR1020087015442A patent/KR20080074193A/ko not_active Ceased
  • 2006-11-27 PL PL06829145T patent/PL1962822T3/pl unknown
  • 2006-11-27 ES ES06829145T patent/ES2341575T3/es active Active
  • 2006-11-27 PT PT06829145T patent/PT1962822E/pt unknown
  • 2006-11-27 DE DE602006011650T patent/DE602006011650D1/de active Active
  • 2006-11-27 US US12/085,405 patent/US8268888B2/en active Active
  • 2006-11-27 EP EP06829145A patent/EP1962822B1/en active Active
  • 2006-11-27 CA CA2630848A patent/CA2630848C/en active Active
  • 2006-11-27 JP JP2008541658A patent/JP5108781B2/ja active Active
  • 2006-11-27 WO PCT/EP2006/011367 patent/WO2007060011A1/en not_active Ceased
  • 2006-11-27 AT AT06829145T patent/ATE454144T1/de active
  • 2006-11-27 NZ NZ568367A patent/NZ568367A/en unknown
  • 2006-11-27 DK DK06829145.9T patent/DK1962822T3/da active
• 2008
  • 2008-05-25 IL IL191690A patent/IL191690A/en active IP Right Grant

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events